Repligen Receivables 2010-2024 | RGEN

Repligen receivables for the quarter ending September 30, 2024 were $0.123B, a 2.44% increase year-over-year.

  • Repligen receivables for 2023 were $0.124B, a 6.81% increase from 2022.
  • Repligen receivables for 2022 were $0.116B, a 1% decline from 2021.
  • Repligen receivables for 2021 were $0.117B, a 64.48% increase from 2020.

Repligen Receivables 2010-2024 | RGEN

  • Repligen receivables for 2023 were $0.124B, a 6.81% increase from 2022.
  • Repligen receivables for 2022 were $0.116B, a 1% decline from 2021.
  • Repligen receivables for 2021 were $0.117B, a 64.48% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$158.3B
Bristol Myers Squibb (BMY)$119.4B
Vertex Pharmaceuticals (VRTX)$116.1B
Gilead Sciences (GILD)$112.4B
CSL (CSLLY)$87.2B
Regeneron Pharmaceuticals (REGN)$81.1B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.6B
Alnylam Pharmaceuticals (ALNY)$31.6B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$23B
Illumina (ILMN)$22.2B
BeiGene (BGNE)$18.6B
Moderna (MRNA)$15.8B
Incyte (INCY)$13.8B
Genmab (GMAB)$13.7B
Insmed (INSM)$13.1B
BioMarin Pharmaceutical (BMRN)$12.2B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.1B
Intra-Cellular Therapies (ITCI)$9.1B
Ascendis Pharma (ASND)$7.9B
Jazz Pharmaceuticals (JAZZ)$7.7B